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Anatomical and physiological studies conducted in the 1960s identified the periaqueductal gray (PAG) and its descending
projections to the rostral ventromedial medulla (RVM) and spinal cord dorsal horn, as a primary anatomical pathway mediating
opioid-based analgesia. Since these initial studies, the PAG-RVM-spinal cord pathway has been characterized anatomically and
physiologically in a wide range of vertebrate species. Remarkably, the majority of these studies were conducted exclusively in males
with the implicit assumption that the anatomy and physiology of this circuit were the same in females; however, this is not the case.
It is well established that morphine administration produces greater antinociception in males compared to females. Recent studies
indicate that the PAG-RVM pathway contributes to the sexually dimorphic actions of morphine. This manuscript will review our
anatomical, physiological, and behavioral data identifying sex diﬀerences in the PAG-RVM pathway, focusing on its role in pain
modulation and morphine analgesia.
Copyright © 2009 D. R. Loyd and A. Z. Murphy. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. Introduction
It was first reported that electrical stimulation of the
midbrain periaqueductal gray (PAG) produced profound
analgesia in the male rat in 1969 [1]. Since then, the
anatomical and physiological organization of the PAG and its
descending projections to the rostral ventromedial medulla
(RVM) and dorsal horn of the spinal cord have been well
characterized in a variety of species, including the rat [2–
9], cat [10–18], primate [19, 20], and rabbit [21] (see
Figure 1). The PAG-RVM-spinal cord pathway comprises an
essential neural circuit for opioid-based antinociception [6,
18, 22]. Intra-PAG administration of the mu opioid receptor
(MOR) agonist morphine, the most commonly prescribed
opiate for persistent pain relief, produces naloxone-reversible
analgesia [23] as well as naloxone-reversible excitation of
RVM neurons [7, 24, 25]. Similarly, lesions of the PAG
or intra-PAG administration of MOR antagonists [26–29]
attenuate the antinociceptive eﬀects of systemic morphine
across a wide range of analgesiometric tests [30]. Studies
utilizing autoradiography, immunohistochemistry, and in
situ hybridization have shown that the PAG contains a high
density of MOR [31–38], with approximately 27–50% of
PAG neurons retrogradely labeled from the RVM expressing
MOR [35, 37].
While it is well established that the PAG-RVM-spinal
cord pathway is essential for the analgesic actions of both
systemic and intra-PAG morphine, these early studies were
conducted exclusively in male subjects. Only recently have
studies begun including “sex” as an independent vari-
able, and it is becoming increasingly clear that morphine
does not produce the same degree of antinociception in
males and females, especially following the induction of
persistent pain. Sex diﬀerences in morphine potency were
first reported in rodents in the late 1980s, when it was
shown that systemic morphine administration produced
a significantly greater degree of antinociception in males
using acute pain assays [39–42]. This phenomenon has
been repeated in multiple studies employing animal models
of pain, including orofacial [43] and visceral [44, 45]
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pain models, as well as persistent somatic pain models
[38, 46–52]. Although results on the contrary are also
reported, generally these studies have shown that mor-
phine produces a significantly greater degree of analge-
sia in males in comparison to females. Indeed, we have
recently reported that male rats have a significantly higher
MOR expression in the PAG, which is positively correlated
with morphine analgesia in male but not female rats
[38].
Recently, clinical studies in humans have also reported
sex diﬀerences in morphine analgesia. Of the limited number
of studies that examined “gender” or “sex” as an independent
variable, it has been reported that males experience greater
morphine analgesia compared to females [53–55]. In fact,
one study reported that females required 30% more mor-
phine to reach the same level of analgesia as males [55].
Similar to the rodent literature, the results in human studies
are not unequivocal. Sarton et al. [56] reported greater
morphine analgesia in females, while two studies reported
no sex diﬀerence [57, 58]. Sex diﬀerences in morphine
consumption also have been reported [59]; however, given
that the majority of negative side eﬀects associated with
morphine consumption, including nausea, headache, and
dysphoria [57, 60], are exacerbated in females compared to
males, morphine consumption is not a reliable indicator of
morphine analgesia.
Sex diﬀerences in opioid analgesia are not limited to
mu opioid agonists. In both human and animal studies,
sex diﬀerences in the analgesic eﬀects of kappa or delta
opioid agonists have also been reported, although again, not
without controversy [61–65]. Several factors are likely to
contribute to the disparate results between studies reporting
the presence or absence of a sex diﬀerence in opioid analgesia,
including diﬀerences in the type of pain being examined
(e.g., experimental acute pain versus postoperative pain
versus a chronic pain state), the route of drug administration
(e.g., oral versus intravenous versus intrathecal), the strain
diﬀerences in the rodents studies, and the eﬃcacy of the
opiate being administered. Sex diﬀerences in basal pain
sensitivity, as well as estrous cycle eﬀects, may also contribute
[54, 55, 57, 66–79].
While it is clear that sex diﬀerences in opioid anal-
gesia are not a simple and straightforward phenomenon,
when sex diﬀerences are reported, they are not trivial in
magnitude. In our persistent inflammatory [38, 46] and
visceral pain [44, 45] studies, the ED50 for females is
twice the ED50 of males. Similarly, morphine is approxi-
mately 5-fold more potent in producing antihyperalgesia
in arthritic males compared to arthritic females [52]. Sex
diﬀerences in morphine analgesia are not due to sex dif-
ferences in the pharmacokinetics of morphine in humans
[56] or rodents [50]. Rather, sex diﬀerences in morphine
analgesia are likely related to the inherent diﬀerences in
how the central nervous system of males and females
respond to opiates. To date, the mechanism(s) underly-
ing the sexually dimorphic actions of morphine remain
unknown.
Given that the PAG and its descending projections to the
RVM and dorsal horn of the spinal cord provide a primary
Periaqueductal gray
Rostral ventromedial medulla
From periphery
Spinal cord dorsal horn
Figure 1: A schematic of the descending inhibitory pathway for
pain modulation illustrating the projections from the midbrain
periaqueductal gray to the brainstem RVM and the spinal cord
dorsal horn.
pathway for the actions of opiates in pain modulation,
inherent diﬀerences in this pathway could contribute to
the sexually dimorphic actions of morphine. Thus, we
tested three hypotheses: (1) are there sex diﬀerences in the
anatomical organization of the PAG-RVM pathway? (2) is
there a sexually dimorphic response of the PAG-RVM output
neurons to persistent pain? (3) does the administration of
morphine diﬀerentially engage the PAG-RVM pathway in
male and female rats?
2. Sexually Dimorphic Organization of
a Descending Pain Inhibitory Pathway
We used neuroanatomical tract-tracing techniques to exam-
ine whether there were qualitative and/or quantitative diﬀer-
ences in the neural projection from the PAG to the RVM in
male and female rats. Consistent with previous anatomical
studies [2, 80, 81], we reported that the dorsomedial,
lateral and ventrolateral PAG heavily project to the RVM
in both male and female rats [82]. While no qualitative sex
diﬀerences were noted in the overall distribution of PAG-
RVM projection neurons, females had significantly more
PAG-RVM output neurons across the rostrocaudal axis of
the PAG compared to males [83, 84] (Figures 2(a)–2(c)).
The average number of retrogradely labeled cells across
the rostrocaudal extent of the PAG was greater by a third
in female compared to male rats (Figure 3(a)). The most
prominent sex diﬀerence in retrograde labeling was observed
within the lateral and ventrolateral regions of the PAG,
an area known to contain a dense distribution of MOR
[34, 37].
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Figure 2: (a)–(c) Distribution of cells retrogradely labeled (FG+) from the RVM in males (left) and females (right) at three representative
rostrocaudal levels of the periaqueductal gray. Each black circle represents one FG+ cell. (d)–(f) Distribution of PAG cells that were
immunoreactive for AR (closed circles) or ERα (open circles). (g)–(i) Distribution of PAG cells retrogradely labeled from the RVM that
were also immunoreactive for AR (closed stars) or ERα (open stars).
3. Sexually Dimorphic Response of
the PAG-RVM Pathway to Persistent
Inflammatory Pain
Inflammatory pain results in the activation of descend-
ing modulatory circuits [8, 85] and contributes to both
hyperalgesia and antinociception [86–89]. We found that
the persistent inflammatory pain induced by injection of
complete Freund’s adjuvant (CFA) into the rat hindpaw
caused extensive activation of PAG neurons as measured by
Fos labeling. Interestingly, this activation was comparable
(both quantitatively and qualitatively) in male and female
rats [82]. However, when the analysis was restricted to PAG
neurons retrogradely labeled from the RVM, while females
have almost twice the number of PAG-RVM output neurons
in comparison to males, very few of these cells in female
rats expressed inflammation-induced Fos, suggesting that
this circuit is preferentially activated in males (Figure 3(b)).
Indeed we found that, overall, persistent inflammatory pain
activated approximately 43% of PAG-RVM neurons in the
dorsomedial, lateral and ventrolateral PAG of males, but
only half as many PAG-RVM output neurons were activated
by inflammatory pain in females. Activation of the PAG
and its descending outputs to the RVM results primarily in
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Figure 3: (a) Mean number of PAG cells retrogradely labeled from the RVM across the rostrocaudal axis in males (left) and females (right).
(b) Percentage of Fos-positive neurons that were retrogradely labeled from the RVM in males (left) and females (right) following twenty-four
hours of inflammation. (c) Average of the percentage of AR (left) and ERα (right) receptor-expressing PAG cells retrogradely labeled from
the RVM. (d) Percentage of Fos-positive neurons that were retrogradely labeled from the RVM in males (left) and females (right) following
twenty-four hours of inflammation and one hour of morphine (5 mg/kg).
the inhibition of dorsal horn neuronal responses to acute
noxious stimuli [90–95]; therefore, one would predict that
given the greater activation of the circuit in males than
females, males should have displayed reduced hyperalgesia
following induction of plantar inflammation. However, in
our behavioral studies, we found no sex diﬀerences in
either baseline withdrawal latencies or in CFA-induced
hyperalgesia. Therefore, our finding that the PAG-RVM
descending circuit is not being engaged to the same degree by
persistent inflammatory pain in males and females suggests
that there is an alternative mechanism for endogenous pain
modulation in female rats [96–99].
We have recently begun exploring this possibility using
combinatorial anterograde and retrograde tract-tracing in
combination with persistent pain-induced Fos labeling. The
results of these studies suggest that there are indeed sex
diﬀerences in both the eﬀerent and aﬀerent projections of the
PAG. Specifically, the amygdala, ventromedial hypothalamus,
and periventricular nucleus project more heavily to the PAG
in females than males. In contrast, the medial preoptic
area, parabrachial nucleus, and locus coeruleus project more
heavily to the PAG in males than females [100]. In addition,
our data indicate that the projections to the parabrachial
nucleus, locus coeruleus, and the A5/A7 noradrenergic cell
group appear to be greater in males (Loyd and Murphy,
unpublished observations). Obviously, further research on
the anatomy and physiology of pain modulatory circuits in
females is warranted.
4. Sex Differences in the Activation of the
Descending Inhibitory Pathway by Morphine
Although sex diﬀerences in PAG-RVM output neuron acti-
vation do not appear to contribute to sex diﬀerences in
pain, they do appear to contribute to sex diﬀerences in
morphine analgesia. Until recently, all studies examining the
mechanisms of morphine action in the PAG were conducted
exclusively in males; therefore it was unknown whether
morphine administration has the same physiological eﬀect
on PAG neurons in females. Electrophysiological studies of
PAG neurons are limited because they examine the response
of a single neuron [7, 17, 101–109]. We have addressed this
problem by using tract-tracing techniques and Fos labeling
to measure the activity of populations of PAG-RVM neurons
in the PAG of males and females.
Systemic morphine administration attenuates the per-
sistent pain-induced Fos expression within the PAG of
male but not female rats [82] and is consistent with our
data showing that the ED50 for systemic morphine is
approximately twofold higher in females compared to males
whether administered systemically [46] or directly into the
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Figure 4: Distribution of PAG cells expressing Fos (black circles) and cells retrogradely labeled from the RVM expressing Fos (stars)
following: (a)–(c) one 5 mg/kg dose of morphine; (d)–(f) one 5 mg/kg dose of morphine per day for three consecutive days; (g)–(i) or
two 5 mg/kg doses of morphine per day for three consecutive days in males (left) and females (right) at three representative rostrocaudal
levels of the PAG.
PAG [38]. Interestingly, morphine administration, in the
absence of pain, resulted in a twofold greater activation
of PAG neurons compared to saline administration [84].
No sex diﬀerence was observed in the activation of PAG
neurons by morphine (see the black circles in Figures 4(a)–
4(c)), suggesting that in the absence of pain, morphine is
equipotent in its ability to depolarize PAG neurons. However,
when the analysis was limited to PAG neurons projecting
to the RVM, the number of neurons activated by morphine
was consistently and significantly higher in males compared
to females (see the stars in Figures 4(a)–4(c)) [84]. Indeed,
approximately half of PAG-RVM neurons in males were
activated by morphine, whereas only 20% were activated in
females (see Figure 3(c)). These results corroborate previous
studies demonstrating that morphine results primarily in the
net excitation of PAG-RVM neurons, most likely through the
removal of tonic GABA inhibition [35, 104, 110, 111]. The
finding that very few PAG-RVM neurons were activated by
morphine in females suggests that morphine may be limited
in eﬀectiveness as a pain modulator.
Given that more PAG neurons project to the RVM
in female compared to male rats, it is possible that pain
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Figure 5: Percentage of Fos-positive neurons that were retrogradely
labeled from the RVM (%Fos in FG+ cells) in male (solid bars)
and female (open bars) rats injected with either morphine or saline
once or twice daily for three days for the rostral ((a); Bregma−6.72,
−7.04, −7.74) and caudal ((b); Bregma −8.00, −8.30, −8.80) PAG.
A decrease in labeling is evident with an increase in the number
of morphine injections for male rats. The # indicates a significant
eﬀect of treatment and the ∗ indicates a significant eﬀect of sex.
Saline: morphine naı¨ve; 1 dose: saline pretreatment followed by one
dose of morphine; 3 doses: one dose of morphine per day; 6 doses: two
doses of morphine per day.
modulation in females is less dependent on opioids. If this
is the case, then direct activation of PAG output neurons
should produce greater antinociception in females, not
males. Microinjection of the GABA antagonist bicuculline
into the PAG produces antinociception [110, 112] by disin-
hibiting output neurons. Surprisingly, even though females
have more output neurons, the antinociceptive eﬀect of
microinjecting bicuculline into the PAG is greater in males
[113].
5. Sex Differences in the Development of
Tolerance to Morphine
Repeated or continuous administration of morphine into the
ventrolateral PAG of male rats has been shown to result in the
development of tolerance [26, 114–118]. In addition, block-
ing opioid binding sites in the ventrolateral PAG attenuates
the development of tolerance to systemically administered
morphine [26]. Tolerance appears to be mediated by a
reduction in MOR signaling eﬃcacy in PAG neurons [119],
an eﬀect that is reversed when MOR coupling is enhanced via
upregulated adenylate cyclase activity [120]. If the PAG-RVM
pathway is essential for the development of tolerance, then
activation of the PAG-RVM pathway by morphine should
decline as tolerance develops, and changes in the activation
of this pathway would correlate with sex diﬀerences in the
development of tolerance to morphine. These hypotheses
were tested in male and female rats using behavioral testing
(hot plate) and immunohistochemistry to map the activation
of the PAG-RVM pathway following repeated morphine
administration.
Morphine was administered once or twice a day for three
days in rats that had previously received retrograde tracer
injections into the RVM. To examine the activation of PAG-
RVM neurons during the development of tolerance, males
and females were both administered 5 mg/kg of morphine,
the ED50 for males. Repeated administration of systemic
morphine induced tolerance in males to a significantly
greater extent than in females [83], consistent with previous
research administering equipotent doses of morphine to
examine sex diﬀerences in tolerance [47]. The half maximal
antinociceptive eﬀect of a single injection of morphine
following the development of morphine tolerance was two
times greater for female compared to male rats. In parallel,
the activation of PAG-RVM neurons was significantly atten-
uated following repeated morphine administration in males
[83]. While there was no sex diﬀerence in the activation
of the PAG following three doses or six doses of morphine
over three days (see the black circles in Figures 4(d)–4(i)),
the activation of the PAG-RVM projection neurons steadily
declined in males only (see the stars in Figures 4(d)–4(i)).
Activation of the PAG-RVM pathway by morphine in female
rats was minimal, and therefore did not decline significantly
following repeated administration of morphine (Figure 5;
previously published [83]).
While together, these data provide compelling support
for a central role of the PAG in the development of morphine
tolerance; these studies administered the male ED50 dose
of morphine. While a single administration of this dose
of morphine resulted in comparable activation of the PAG
in males and females, it was suboptimal in producing
behaviorally defined antinociception in females and may
account for why females did not develop tolerance to the
same degree as males. Future studies employing sex-specific
ED50 doses are clearly warranted.
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6. Role of Gonadal Hormones in Sex
Differences in Morphine Analgesia
Studies in rodents indicate that sex diﬀerences in the orga-
nizational and activational eﬀects of the gonadal hormones
estradiol and testosterone influence morphine analgesia.
For example, male rats castrated at birth demonstrate
decreased morphine potency in adulthood, while female
rats masculinized at birth demonstrate greater morphine
potency in adulthood [121, 122]. Similarly, morphine is
less eﬀective in gonadectomized adult males and is more
eﬀective in ovariectomized adult females [40, 123–128];
these eﬀects can be reversed with hormone replacement
[44, 123, 129]. Moreover, the antinociceptive potency of
morphine has been reported to be greater during diestrus,
when circulating estradiol levels are lowest [43, 124, 125,
127, 130], which is corroborated by our recent findings
that MOR expression in female rats is the highest during
diestrus compared to proestrus and estrus [38]. Recently,
it was reported that microinjection of morphine directly
into the PAG produces less antinociception during estrus
(after estradiol peaks), while there was no sex diﬀerence
in morphine potency between diestrus females and males
[131]. We have recently reported similar findings in which
the antihyperalgesic eﬀects of intra-PAG morphine were
significantly greater in females in diestrus in comparison to
proestrus and estrus [38].
The anatomical substrate(s) whereby gonadal steroids
influence pain and analgesia is unknown. Both androgen
(AR) and estrogen receptorsα (ERα) have been localized
in the PAG in the male rat [132]. Although it is not
known if these receptors are present in the female rat, they
have been localized in other species including the female
cat [12], golden hamster [133], guinea pig [134], and the
rhesus monkey [135, 136]. To date, however, the anatomical
distribution of both types of steroid receptor within the PAG
in reference to cells projecting to the RVM is not known.
We have combined neuroanatomical tract-tracing tech-
niques and steroid receptor immunohistochemistry to char-
acterize the expression of AR and ERα in the PAG-
RVM pathway of male and female rats [137]. In these
studies, we found that males had a significantly greater
number of AR immunoreactive neurons localized within
the dorsomedial, lateral and ventrolateral PAG compared to
females. Interestingly, both the qualitative and quantitative
expression of ERα in the PAG was comparable between
the sexes (see Figures 2(d)–2(f)). Both receptor types were
preferentially localized within the dorsomedial, lateral and
ventrolateral subdivisions of the PAG and increased in den-
sity along the rostrocaudal axis of the PAG with the highest
expression localized within the caudal PAG. In addition,
30–37% of PAG-RVM output neurons expressed AR or
ERα (Figure 3(d)) with the highest density of colabeling
in the lateral/ventrolateral region of PAG. ERa and AR
colocalization in PAG neurons projecting to the RVM was
comparable between the sexes [137] (Figures 2(g)–2(i)).
The high density of steroid receptors localized on PAG-
RVM output neurons may contribute to our observed sex
diﬀerences in morphine analgesia. Although there was no sex
diﬀerence in the anatomical localization of gonadal steroid
receptors in the PAG despite the higher density of AR in
males, 27–50% of PAG-RVM neurons contain MOR [37].
Given that morphine activates more of these neurons in male
compared to female rats, the interaction between morphine
and sex hormones is likely greater in the PAG of male
compared to female rats.
There are several mechanisms whereby gonadal steroids
may modulate opioid-sensitive PAG-RVM output neurons,
thereby potentially resulting in a dimorphic response to
morphine. First, estradiol has been shown to uncouple the
MOR from G protein-gated inwardly rectifying potassium
channels [138] resulting in an attenuation of morphine-
induced hyperpolarization. Second, estradiol has also been
shown to induce MOR internalization [139], thereby reduc-
ing available opioid binding sites on the cell membrane.
Interestingly, ERα is required for estradiol-induced MOR
internalization [140] supporting the hypothesis that colocal-
ization of MOR and ERα in the PAG-RVM output neurons
may provide a pain modulatory mechanism. Interestingly,
administration of estradiol to gonadectomized males rein-
states morphine analgesia while dihydrotestosterone does not
[141], suggesting that estrogens aﬀect morphine potency in
both male and female rats [130].
7. Conclusions
Research spanning for four decades has shown that the PAG
and its descending projections to the RVM and spinal cord
dorsal horn constitute an essential neural circuit for opioid-
based analgesia. During the last half of that period, numerous
rodent and human studies have established sex diﬀerences
in the antinociceptive and analgesic eﬀects of morphine;
however, the neural mechanisms underlying the sexually
dimorphic actions of morphine remain poorly understood. It
is now clear that the anatomical and physiological character-
istics of the PAG and its descending projections to the RVM
are sexually dimorphic, with clear biological consequences
in terms of morphine potency. Our studies, as well as
those of others, have shown that morphine is less potent in
females compared to males in the alleviation of persistent
pain. Future research eﬀorts utilizing female subjects in
both the investigation of persistent pain mechanisms and
identification of both eﬀective and potent pain therapeutics
are clearly warranted.
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